A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days

Seliciclib (CYC202; R-roscovitine) is the first selective, orally bioavailable inhibitor of cyclin-dependent kinases 1, 2, 7 and 9 to enter clinical trial. Preclinical studies showed antitumour activity in a broad range of human tumour xenografts. A phase I trial was performed with a 7-day b.i.d. p....

Descripción completa

Detalles Bibliográficos
Autores principales: Benson, C, White, J, Bono, J De, O'Donnell, A, Raynaud, F, Cruickshank, C, McGrath, H, Walton, M, Workman, P, Kaye, S, Cassidy, J, Gianella-Borradori, A, Judson, I, Twelves, C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360206/
https://www.ncbi.nlm.nih.gov/pubmed/17179992
http://dx.doi.org/10.1038/sj.bjc.6603509

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360206/
https://www.ncbi.nlm.nih.gov/pubmed/17179992
http://dx.doi.org/10.1038/sj.bjc.6603509

Ejemplares similares